AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$ICLR

CLIMAX JOHN DR sold $876K of ICLR

CLIMAX JOHN DR sold 5,005 shares of ICON PLC (ICLR) at $175.00 ($0.88M total) on 2026-09-16.

Original reporting
SEC EDGAR · CLIMAX JOHN DR
Published Sep 18, 2026, 10:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 10:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ICLR
Bearish
medium confidence
Mentioned
$ICLR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICLRBearishLow
01

Why it matters

The director's sale is modest but may be interpreted as a negative signal by short-term traders.

02

Market read

New insider sale provides fresh data for traders monitoring ICON PLC; limited broader market effect.

03

What to watch

Potential tax planning or portfolio rebalancing; no 10b5-1 plan suggests discretionary sale.

Relevance 5/10Novelty 4/10Timing: Filed Sep 18 2026

Background

Form 4 filing discloses insider transactions; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$ICLRBearishMedium confidence
Context

Director Climax John Dr sold 5,005 shares of ICON PLC for $875,875 on Sep 16, 2026.

Expected impact

Potential slight dip in ICLR price, likely within 1-2% range.

Evidence & confidence

Sale size is modest relative to holdings; director level insider, no 10b5-1 plan, may be routine diversification.

Market effects

Sector

Minimal impact on healthcare services sector.

Regional

Limited to UK/US investors tracking ICON.

Global

Low global relevance.

Counterpoint

What could challenge this read

Insider sale could be unrelated to company outlook; may not affect price.

Key entities

  • Company
    ICON PLC

    Healthcare services provider listed on NYSE as ICLR.

  • Insider
    Climax John Dr

    Director of ICON PLC.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ICLR insider trading history →

Related articles

JUL 29
$ICLRMedAI 9/10

ICON plc: ICON Reports Second Quarter 2026 Results

ICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.

finanznachrichten.de3 min
JUL 29
$ICLRHighAI 8/10

ICON PLC (ICLR): Financial results for Q2 2026

ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ICON Reports Second Quarter 2026 Results Highlights • Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. • Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. • GAAP net income for

SEC EDGAR 6-K2 min
JUL 28
$ICLRMed

ICON stock surges 7% on Anthropic AI partnership for trials By Investing.com

ICON plc (NASDAQ:ICLR) shares rose about 7.8% after the company announced a multi-year partnership with Anthropic to integrate Claude AI into its Orbis clinical trial platform. ICON said the collaboration will add four production capabilities, including site intelligence and enrollment risk detection, and will roll out Claude across roles. ICON cited enrollment delays affecting up to 80% of trials.

investing.com3 min
JUL 28
$ICLRMed

ICON, Anthropic Sign Multi-Year Partnership Deal To Advance AI Capabilities, Stock Up In Pre-Market

ICON Public Limited Company (ICLR) said it signed a multi-year partnership with Anthropic to integrate Claude AI across the clinical trial lifecycle using ICON’s Orbis platform. ICON plans to work with Anthropic’s life sciences team and deploy Claude Code, Claude, and Claude Science. The company cited CEO Barry Balfe. In pre-market, ICLR rose to $177.69, up 5.28% on Nasdaq.

rttnews.com2 min